Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VLP‐factory™ and ADDomer©: Self‐assembling Virus‐Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope Display

1 Mar 2021

Abstract excerpt

Abstract Virus‐like particles (VLPs) play a prominent role in vaccination as safe and highly versatile alternatives to attenuated or inactivated viruses or subunit vaccines. We present here two innovations, VLP‐factory™ and ADDomer©, for creating VLPs displaying entire proteins or peptide epitopes as antigens, respectively, to enable efficient vaccination. For producing these VLPs, we use MultiBac, a baculovirus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Transgenic Plants and Applications
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33729713
DOI: 10.1002/cpz1.55

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VLP‐factory™ and ADDomer©: Self‐assembling Virus‐Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope DisplayPMID 33729713Read ↗

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read ↗

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformSemantic proximity Read ↗

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read ↗

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read ↗

Advances and challenges in enveloped virus-like particle (VLP)-based vaccinesSemantic proximity Read ↗

Recent Progress on the Versatility of Virus-Like ParticlesSemantic proximity Read ↗

Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine designSemantic proximity Read ↗

Novel Library Assembly Technique for Developing Nanobodies Targeting IPNv VP2 ProteinSemantic proximity Read ↗

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancerSemantic proximity Read ↗

The coming of age of virus-like particle vaccinesSemantic proximity Read ↗

SARS-CoV-2 Virus like Particles produced by a single recombinant baculovirus generate potent neutralizing antibody that protects against variant challengeSemantic proximity Read ↗

Engineering the PP7 Virus Capsid as a Peptide Display PlatformSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.